---
title: "Cancer Treatment Modalities"
order: 3
category: "Oncology"
---

# Cancer Treatment Modalities

## Overview

Cancer treatment has evolved dramatically over the past several decades, transitioning from a one-size-fits-all approach to personalized, multimodal therapy based on tumor biology, molecular characteristics, and patient factors. The primary treatment modalities include surgery, radiation therapy, systemic therapy (chemotherapy, targeted therapy, immunotherapy, and hormonal therapy), and supportive care. Understanding the principles, indications, mechanisms, and toxicities of each modality is essential for comprehensive oncology care.

### Goals of Cancer Treatment

**Curative intent**:
- Complete eradication of cancer
- Early-stage localized disease
- Selected metastatic cancers (testicular, some lymphomas)
- Long-term disease-free survival

**Palliative intent**:
- Symptom relief
- Improve quality of life
- Prolong survival
- Metastatic or advanced incurable disease

**Adjuvant therapy**:
- After definitive local treatment (surgery/radiation)
- Eradicate micrometastatic disease
- Reduce recurrence risk

**Neoadjuvant therapy**:
- Before definitive local treatment
- Downstage tumor (improve resectability)
- Assess treatment response (in vivo chemosensitivity)
- Early treatment of micrometastases

### Multidisciplinary Approach

**Tumor boards**:
- Medical oncology, surgical oncology, radiation oncology
- Pathology, radiology
- Nursing, social work, palliative care
- Discussion of complex cases, treatment planning

## Surgery

### Principles of Surgical Oncology

**Goals**:
- Complete tumor resection with negative margins (R0 resection)
- Adequate lymph node assessment/resection
- Minimize morbidity
- Preserve function when possible

**Margin status**:
- **R0**: Negative margins (no residual tumor)
- **R1**: Microscopic residual disease
- **R2**: Macroscopic residual disease (gross residual)

### Types of Cancer Surgery

**Diagnostic surgery**:
- **Biopsy**: Obtain tissue for diagnosis
  - Excisional: Remove entire lesion (small tumors, lymph nodes)
  - Incisional: Remove portion of tumor
  - Core needle: Image-guided, adequate for most diagnoses
  - Fine needle aspiration (FNA): Cytology only, limited role
- Ensure adequate tissue for histology, immunohistochemistry, molecular testing

**Staging surgery**:
- Determine extent of disease
- Laparotomy/laparoscopy for peritoneal staging
- Sentinel lymph node biopsy (breast, melanoma)
- Mediastinoscopy (lung cancer)

**Definitive surgery** (curative):
- **Wide local excision**: Tumor + margin of normal tissue
- **Radical resection**: Tumor + regional lymph nodes ± adjacent organs
  - Examples: Radical mastectomy, Whipple procedure, radical prostatectomy
- **Organ-sparing surgery**: Preserve function (lumpectomy, partial nephrectomy)

**Cytoreductive (debulking) surgery**:
- Remove bulk of tumor when complete resection not possible
- Ovarian cancer, mesothelioma
- Improve efficacy of systemic therapy

**Palliative surgery**:
- Symptom relief (not curative)
- Bowel obstruction bypass
- Decompression (spinal cord compression)
- Hemorrhage control

**Reconstructive surgery**:
- Restore form and function after resection
- Breast reconstruction, head and neck reconstruction

**Prophylactic surgery**:
- Remove at-risk tissue before cancer develops
- Prophylactic mastectomy (BRCA mutation)
- Prophylactic colectomy (FAP)
- Prophylactic thyroidectomy (MEN2)

### Minimally Invasive Surgery

**Laparoscopic/thoracoscopic**:
- Smaller incisions, faster recovery
- Oncologic outcomes equivalent to open (for many cancers)
- Colon, gastric, lung cancer

**Robotic-assisted**:
- Enhanced dexterity, 3D visualization
- Prostate, gynecologic, rectal cancer

### Sentinel Lymph Node Biopsy

**Principle**:
- Identify and remove first draining lymph node(s)
- If negative, avoid complete lymphadenectomy
- Reduce morbidity (lymphedema)

**Indications**:
- Breast cancer (clinically node-negative)
- Melanoma
- Selected other solid tumors

**Technique**:
- Inject radiotracer and/or blue dye near tumor
- Identify sentinel node(s) with gamma probe/visual inspection
- Resect and analyze

### Complications

- Bleeding, infection
- Organ dysfunction (resection of functional tissue)
- Lymphedema (after lymph node dissection)
- Chronic pain
- Cosmetic/functional deficits

## Radiation Therapy

### Principles of Radiation Oncology

**Mechanism**:
- Ionizing radiation damages DNA (direct and indirect via free radicals)
- Primarily affects rapidly dividing cells (cancer cells)
- Normal tissue also affected (limiting factor)

**Radiobiology**:
- **Four Rs**: Repair (sublethal damage), Reassortment (cell cycle redistribution), Repopulation (tumor regrowth), Reoxygenation (hypoxic cells become oxygenated)
- Fractionation exploits differential repair between normal and tumor tissue

**Dose units**:
- **Gray (Gy)**: 1 Gy = 1 joule/kg
- Typical curative doses: 50-70 Gy (1.8-2 Gy/fraction)

**Treatment volume**:
- **Gross tumor volume (GTV)**: Visible tumor
- **Clinical target volume (CTV)**: GTV + suspected microscopic extension
- **Planning target volume (PTV)**: CTV + margin for setup variation and organ motion

### Types of Radiation Therapy

**External beam radiation therapy (EBRT)**:
- Radiation delivered from external source (linear accelerator)
- Most common type

*Conventional EBRT*:
- 3D conformal radiation therapy (3D-CRT): Shaped beams, imaging-based planning

*Advanced EBRT*:
- **Intensity-modulated radiation therapy (IMRT)**: Variable beam intensity, highly conformal, spares organs at risk
  - Common for head/neck, prostate, GI cancers
- **Stereotactic body radiation therapy (SBRT)**: Very high dose per fraction (5-10 fractions), small target, high precision
  - Early lung cancer, liver/spine metastases
- **Stereotactic radiosurgery (SRS)**: Single high-dose fraction to brain (misnomer, no surgery)
  - Brain metastases, AVMs, acoustic neuromas
- **Proton beam therapy**: Charged particles, no exit dose (Bragg peak)
  - Pediatrics, skull base, less normal tissue toxicity

**Brachytherapy** (internal radiation):
- Radioactive source placed in or near tumor
- Very high local dose, rapid dose fall-off

*Low-dose rate (LDR) brachytherapy*:
- Permanent seed implants or temporary implants (days)
- Prostate cancer (I-125, Pd-103 seeds)
- Gynecologic malignancies (cervical, endometrial)

*High-dose rate (HDR) brachytherapy*:
- Temporary catheter-based, minutes per fraction
- Prostate boost, gynecologic, breast (partial breast irradiation)

*Other forms*:
- Radioembolization (Y-90 microspheres for liver tumors)
- Radiopharmaceuticals (systemic): Radium-223 (bone metastases), I-131 (thyroid cancer)

### Indications for Radiation Therapy

**Curative intent**:
- Definitive radiation alone: Early head/neck, cervical, anal cancer
- Adjuvant radiation: After surgery (breast, rectal, sarcoma)
- Neoadjuvant radiation: Before surgery (rectal)
- Concurrent chemoradiation: Chemotherapy radiosensitizer (lung, esophageal, GI)

**Palliative intent**:
- Bone metastases (pain relief)
- Brain metastases
- Spinal cord compression
- Superior vena cava syndrome
- Bleeding control
- Airway obstruction

### Acute Toxicities (During or Shortly After Treatment)

**General**:
- Fatigue (most common)
- Skin changes: Erythema, desquamation (radiation dermatitis)

**Site-specific**:
- **Head and neck**: Mucositis, xerostomia, dysphagia, dermatitis, taste changes
- **Chest**: Esophagitis (dysphagia, odynophagia), pneumonitis (cough, dyspnea)
- **Abdomen/pelvis**: Nausea, diarrhea, cystitis (urinary frequency, dysuria), proctitis
- **Brain**: Hair loss, skin changes, fatigue, headache

### Late Toxicities (Months to Years After Treatment)

**General**:
- Fibrosis (subcutaneous, organ)
- Secondary malignancies (solid tumors, leukemia) - rare, 1-2% at 10+ years

**Site-specific**:
- **Head and neck**: Permanent xerostomia, hypothyroidism, carotid stenosis, osteoradionecrosis (jaw)
- **Chest**: Pulmonary fibrosis, pericarditis, coronary artery disease, esophageal stricture
- **Abdomen/pelvis**: Bowel stricture/obstruction, chronic diarrhea, fistula, sexual dysfunction
- **Brain**: Cognitive impairment, white matter changes, necrosis (rare)

### Management of Toxicities

**Skin**:
- Gentle cleansing, avoid irritants
- Topical corticosteroids, silver sulfadiazine (if desquamation)

**Mucositis/esophagitis**:
- Salt/soda rinses, viscous lidocaine, magic mouthwash
- Opioids for pain
- Nutritional support (feeding tube if needed)

**Nausea**:
- 5-HT3 antagonists (ondansetron), dexamethasone

**Diarrhea**:
- Loperamide, dietary modification
- Cholestyramine (bile acid malabsorption)

**Pneumonitis**:
- Corticosteroids (prednisone 0.5-1 mg/kg)

## Chemotherapy

### Principles of Chemotherapy

**Mechanism**:
- Cytotoxic agents targeting rapidly dividing cells
- Affect both cancer cells and normal rapidly dividing cells (bone marrow, GI mucosa, hair follicles)

**Cell cycle specificity**:
- **Cell cycle-specific**: Active in particular phase (S phase: antimetabolites; M phase: vinca alkaloids, taxanes)
- **Cell cycle-nonspecific**: Active in all phases (alkylating agents, anthracyclines)

**Log-kill hypothesis**:
- Each chemotherapy cycle kills constant fraction of cells (not constant number)
- Multiple cycles required for cure

**Combination chemotherapy**:
- Rationale: Different mechanisms, non-overlapping toxicities, prevent resistance
- More effective than single agents for most cancers

### Classes of Chemotherapy

**Alkylating agents**:
- **Mechanism**: DNA cross-linking, strand breaks
- **Examples**: Cyclophosphamide, ifosfamide, cisplatin, carboplatin, oxaliplatin, temozolomide
- **Toxicities**:
  - Cisplatin: Nephrotoxicity (hydration, magnesium wasting), ototoxicity, peripheral neuropathy
  - Cyclophosphamide: Hemorrhagic cystitis (mesna prevention), bladder cancer
  - Ifosfamide: Neurotoxicity (confusion, encephalopathy)
  - All: Bone marrow suppression, secondary leukemia

**Antimetabolites**:
- **Mechanism**: Inhibit nucleotide synthesis or incorporation
- **Examples**:
  - 5-Fluorouracil (5-FU), capecitabine: Thymidylate synthase inhibition
  - Methotrexate: Dihydrofolate reductase (DHFR) inhibition
  - Gemcitabine: Ribonucleotide reductase inhibition
  - Cytarabine: DNA polymerase inhibition
- **Toxicities**:
  - 5-FU/capecitabine: Mucositis, diarrhea, hand-foot syndrome, coronary vasospasm (rare)
  - Methotrexate: Mucositis, hepatotoxicity, nephrotoxicity (high-dose requires leucovorin rescue)
  - Gemcitabine: Pulmonary toxicity, thrombotic microangiopathy (rare)

**Anthracyclines**:
- **Mechanism**: DNA intercalation, topoisomerase II inhibition, free radical generation
- **Examples**: Doxorubicin, epirubicin, daunorubicin, idarubicin
- **Toxicities**:
  - **Cardiotoxicity**: Dose-dependent (limit lifetime dose: doxorubicin 450-550 mg/m²), heart failure
  - Red urine (harmless)
  - Alopecia
  - Bone marrow suppression

**Topoisomerase inhibitors**:
- **Topoisomerase I inhibitors**: Irinotecan, topotecan
  - Irinotecan: Diarrhea (early: cholinergic, treat with atropine; late: secretory, treat with loperamide), UGT1A1 polymorphism (increased toxicity in poor metabolizers)
- **Topoisomerase II inhibitors**: Etoposide, teniposide
  - Etoposide: Bone marrow suppression, secondary leukemia (11q23/MLL rearrangement)

**Taxanes**:
- **Mechanism**: Microtubule stabilization (prevent depolymerization), mitotic arrest
- **Examples**: Paclitaxel, docetaxel, cabazitaxel, nab-paclitaxel (albumin-bound)
- **Toxicities**:
  - Hypersensitivity reactions (premedicate with dexamethasone, H1/H2 blockers)
  - Peripheral neuropathy (cumulative)
  - Bone marrow suppression (docetaxel > paclitaxel)
  - Fluid retention (docetaxel)
  - Alopecia

**Vinca alkaloids**:
- **Mechanism**: Microtubule destabilization (inhibit polymerization), mitotic arrest
- **Examples**: Vincristine, vinblastine, vinorelbine
- **Toxicities**:
  - Vincristine: Peripheral neuropathy (dose-limiting), constipation, SIADH
  - Vinblastine: Bone marrow suppression (dose-limiting)
  - **Vesicants**: Severe tissue necrosis if extravasation

### Common Chemotherapy Regimens

**Breast cancer**:
- AC-T: Doxorubicin + cyclophosphamide → paclitaxel
- TC: Docetaxel + cyclophosphamide
- TCH: Docetaxel + carboplatin + trastuzumab (HER2+)

**Colorectal cancer**:
- FOLFOX: 5-FU + leucovorin + oxaliplatin
- FOLFIRI: 5-FU + leucovorin + irinotecan
- CAPOX: Capecitabine + oxaliplatin

**Lung cancer (NSCLC)**:
- Cisplatin/carboplatin + pemetrexed (non-squamous)
- Cisplatin/carboplatin + paclitaxel/docetaxel

**Lymphoma**:
- CHOP: Cyclophosphamide + doxorubicin (hydroxydaunorubicin) + vincristine (Oncovin) + prednisone
- R-CHOP: CHOP + rituximab (anti-CD20)

### Acute Toxicities and Management

**Nausea and vomiting**:
- **Emetogenicity classification**: High (cisplatin, AC), moderate, low, minimal
- **Prophylaxis**: 5-HT3 antagonist (ondansetron, granisetron) + NK-1 antagonist (aprepitant) + dexamethasone (high emetogenic)
- Breakthrough: Olanzapine, metoclopramide, prochlorperazine

**Bone marrow suppression**:
- **Neutropenia**: Nadir 7-14 days, recovery by 21 days (most regimens)
  - Febrile neutropenia (ANC <500, fever ≥38.3°C): Medical emergency, broad-spectrum antibiotics
  - Prophylaxis: G-CSF (filgrastim, pegfilgrastim) if risk >20% or high-risk patient
- **Anemia**: Transfusion if symptomatic, erythropoiesis-stimulating agents (limited use due to thrombotic risk)
- **Thrombocytopenia**: Platelet transfusion if <10,000 (prophylactic) or bleeding

**Mucositis**:
- Salt/soda rinses, viscous lidocaine
- Palifermin (keratinocyte growth factor) for high-dose chemotherapy (stem cell transplant)

**Diarrhea**:
- Loperamide first-line
- If severe: Octreotide

**Alopecia**:
- Common with anthracyclines, taxanes
- Scalp cooling (cold caps) may reduce (not widely available)
- Reversible after treatment

**Extravasation** (vesicants):
- Stop infusion immediately
- Aspirate, do not flush
- Specific antidotes (dexrazoxane for anthracyclines)
- Plastic surgery consult if severe

### Chronic/Late Toxicities

- Cardiotoxicity (anthracyclines, trastuzumab)
- Peripheral neuropathy (platinum, taxanes, vinca alkaloids)
- Nephrotoxicity (cisplatin, ifosfamide)
- Pulmonary fibrosis (bleomycin, busulfan)
- Secondary malignancies (alkylating agents, topoisomerase II inhibitors)
- Infertility (alkylating agents, high-dose chemotherapy)
  - Fertility preservation: Sperm banking, oocyte/embryo cryopreservation
- Cognitive impairment ("chemobrain")

## Targeted Therapy

### Principles

**Mechanism**:
- Target specific molecular pathways or proteins critical for cancer growth
- More selective than chemotherapy (less toxicity to normal cells)
- Requires identification of molecular target (biomarker testing)

### Classes of Targeted Therapy

**Tyrosine kinase inhibitors (TKIs)**:
- Small molecules, oral
- Inhibit intracellular tyrosine kinases

*EGFR inhibitors*:
- **Examples**: Erlotinib, gefitinib, afatinib, osimertinib (NSCLC with EGFR mutations)
- **Toxicities**: Acneiform rash (correlates with efficacy), diarrhea, hepatotoxicity, interstitial lung disease (rare)

*ALK inhibitors*:
- **Examples**: Alectinib, brigatinib, lorlatinib, crizotinib (NSCLC with ALK rearrangement)
- **Toxicities**: Hepatotoxicity, vision changes, edema, bradycardia

*BCR-ABL inhibitors*:
- **Examples**: Imatinib, dasatinib, nilotinib, bosutinib, ponatinib (CML, Ph+ ALL)
- **Toxicities**: Fluid retention, cytopenias, hepatotoxicity
  - Dasatinib: Pleural effusion, pulmonary hypertension
  - Ponatinib: Arterial thrombosis

*Multi-kinase inhibitors*:
- **Examples**: Sorafenib, sunitinib, pazopanib, regorafenib (RCC, HCC, GI stromal tumor)
- **Toxicities**: Hypertension, hand-foot skin reaction, diarrhea, hypothyroidism, hepatotoxicity

*BRAF inhibitors*:
- **Examples**: Vemurafenib, dabrafenib (melanoma, NSCLC with BRAF V600E mutation)
- **Toxicities**: Arthralgias, rash, photosensitivity, squamous cell carcinoma (paradoxical MAPK activation)
- Combined with MEK inhibitor (trametinib, cobimetinib) to reduce resistance and toxicity

**Monoclonal antibodies**:
- Large molecules, intravenous
- Target extracellular proteins or receptors

*HER2 inhibitors*:
- **Trastuzumab**: Monoclonal antibody targeting HER2 (breast, gastric cancer)
  - Toxicity: Cardiotoxicity (reversible, monitor LVEF)
- **Pertuzumab**: HER2 dimerization inhibitor, combined with trastuzumab
- **T-DM1, T-DXd**: Antibody-drug conjugates (trastuzumab + cytotoxic)

*EGFR inhibitors*:
- **Cetuximab, panitumumab**: Monoclonal antibodies (colorectal cancer, head/neck cancer)
  - Require RAS wild-type (KRAS/NRAS)
  - Toxicities: Acneiform rash, hypomagnesemia, infusion reactions

*VEGF inhibitors*:
- **Bevacizumab**: Anti-VEGF antibody (colorectal, lung, ovarian, glioblastoma, RCC)
  - Toxicities: Hypertension, proteinuria, bleeding, thrombosis, GI perforation (rare), impaired wound healing

*CD20 inhibitors*:
- **Rituximab**: Anti-CD20 (B-cell lymphomas, CLL)
  - Toxicities: Infusion reactions, hepatitis B reactivation, progressive multifocal leukoencephalopathy (PML, rare)

**mTOR inhibitors**:
- **Examples**: Everolimus, temsirolimus (RCC, breast cancer)
- **Toxicities**: Mucositis, rash, hyperglycemia, hyperlipidemia, pneumonitis, immunosuppression

**CDK4/6 inhibitors**:
- **Examples**: Palbociclib, ribociclib, abemaciclib (ER+ breast cancer)
- **Toxicities**: Neutropenia, diarrhea (abemaciclib), hepatotoxicity, thromboembolism

**PARP inhibitors**:
- **Examples**: Olaparib, rucaparib, niraparib, talazoparib (BRCA-mutated breast/ovarian/prostate cancer)
- **Mechanism**: Synthetic lethality in homologous recombination deficient tumors
- **Toxicities**: Nausea, fatigue, cytopenias, myelodysplastic syndrome/AML (rare)

**Proteasome inhibitors**:
- **Examples**: Bortezomib, carfilzomib, ixazomib (multiple myeloma)
- **Toxicities**: Peripheral neuropathy (bortezomib), thrombocytopenia, diarrhea, cardiotoxicity (carfilzomib)

### Resistance Mechanisms

- Secondary mutations (e.g., EGFR T790M)
- Bypass pathway activation
- Target amplification
- Epithelial-mesenchymal transition

## Immunotherapy

### Principles

**Mechanism**:
- Harness immune system to recognize and destroy cancer cells
- Overcome tumor immune evasion

### Immune Checkpoint Inhibitors

**PD-1/PD-L1 inhibitors**:
- **Mechanism**: Block PD-1 (on T cells) or PD-L1 (on tumor/immune cells) interaction, restore T cell activity
- **Examples**:
  - Anti-PD-1: Pembrolizumab, nivolumab, cemiplimab
  - Anti-PD-L1: Atezolizumab, durvalumab, avelumab
- **Indications**: Melanoma, NSCLC, RCC, head/neck, urothelial, MSI-high/dMMR solid tumors, many others
- **Biomarkers**: PD-L1 expression (predictive but imperfect), tumor mutational burden (TMB), MSI-high/dMMR

**CTLA-4 inhibitors**:
- **Mechanism**: Block CTLA-4 (on T cells), enhance T cell priming
- **Example**: Ipilimumab
- **Indications**: Melanoma, RCC (combined with nivolumab)

**Combination therapy**:
- Ipilimumab + nivolumab (melanoma, RCC): Higher response rates, more toxicity

**Immune-related adverse events (irAEs)**:
- Autoimmune toxicities from immune activation
- Can affect any organ, most commonly:
  - **Dermatologic**: Rash, pruritus, vitiligo (10-40%)
  - **GI**: Diarrhea, colitis (10-20%)
  - **Hepatic**: Hepatitis (5-10%)
  - **Endocrine**: Thyroiditis, hypophysitis, adrenal insufficiency, type 1 diabetes (5-10%)
  - **Pneumonitis** (3-5%): Cough, dyspnea, infiltrates
  - **Other**: Nephritis, myocarditis (rare but serious), neurologic (neuropathy, encephalitis)
- **Onset**: Median 2-3 months, but can occur anytime (even after stopping)
- **Management**:
  - Grade 1-2: Continue treatment, symptomatic management ± low-dose steroids
  - Grade 3-4: Hold treatment, high-dose corticosteroids (1-2 mg/kg prednisone), consider other immunosuppressants if refractory
  - Endocrinopathies often permanent, require replacement

### CAR T-cell Therapy

**Mechanism**:
- Genetically engineer patient's T cells to express chimeric antigen receptor (CAR) targeting tumor antigen
- Reinfuse to patient after lymphodepletion

**Approved products**:
- Anti-CD19 CAR T cells: Tisagenlecleucel, axicabtagene ciloleucel (B-cell lymphomas, ALL)
- Anti-BCMA CAR T cells: Idecabtagene vicleucel, ciltacabtagene autoleucel (multiple myeloma)

**Toxicities**:
- **Cytokine release syndrome (CRS)**: Fever, hypotension, hypoxia (median onset 2-3 days)
  - Grading: 1 (mild) to 4 (life-threatening)
  - Treatment: Tocilizumab (anti-IL-6), corticosteroids
- **Immune effector cell-associated neurotoxicity syndrome (ICANS)**: Encephalopathy, aphasia, seizures
  - Treatment: Corticosteroids, supportive
- **Cytopenias**: Prolonged, may require transfusion/growth factors
- **Hypogammaglobulinemia**: From B-cell aplasia (anti-CD19), IVIG replacement

### Cytokines

**Interleukin-2 (IL-2)**:
- High-dose IL-2: Melanoma, RCC (curative potential in small subset)
- Toxicities: Capillary leak syndrome, hypotension, multiorgan dysfunction (ICU required)
- Largely replaced by checkpoint inhibitors

**Interferon-alpha**:
- Melanoma (adjuvant), RCC
- Toxicities: Flu-like symptoms, depression, hepatotoxicity
- Limited use now

### Cancer Vaccines

**Sipuleucel-T**:
- Autologous dendritic cell vaccine for metastatic castration-resistant prostate cancer
- Modest survival benefit (4 months)

**HPV vaccine**:
- Preventive (cervical, oropharyngeal cancer)

## Hormonal Therapy

### Breast Cancer

**Estrogen receptor modulation**:
- **Selective estrogen receptor modulators (SERMs)**: Tamoxifen
  - Mechanism: ER antagonist in breast, agonist in bone/uterus
  - Toxicities: Hot flashes, thromboembolism, endometrial cancer (1% cumulative), stroke
- **Selective estrogen receptor degraders (SERDs)**: Fulvestrant
  - IM injection monthly
  - Pure ER antagonist

**Aromatase inhibitors (AIs)**:
- **Examples**: Letrozole, anastrozole, exemestane
- Mechanism: Block conversion of androgens to estrogens (postmenopausal women)
- Toxicities: Arthralgias/myalgias, osteoporosis, fractures, cardiovascular events

**Ovarian suppression/ablation**:
- GnRH agonists (goserelin, leuprolide): Reversible
- Bilateral oophorectomy: Irreversible
- Premenopausal women with high-risk ER+ breast cancer

### Prostate Cancer

**Androgen deprivation therapy (ADT)**:
- **GnRH agonists**: Leuprolide, goserelin
  - Initial testosterone flare (co-administer antiandrogen for 1-2 weeks)
- **GnRH antagonists**: Degarelix, relugolix
  - No flare
- **Bilateral orchiectomy**: Surgical castration

**Toxicities**:
- Hot flashes, decreased libido, erectile dysfunction
- Osteoporosis, fractures (bone-targeted therapy: denosumab, zoledronic acid)
- Metabolic syndrome: Weight gain, insulin resistance, cardiovascular risk
- Cognitive changes, depression, fatigue

**Androgen receptor antagonists**:
- **First generation**: Bicalutamide, flutamide, nilutamide
- **Second generation**: Enzalutamide, apalutamide, darolutamide
  - More potent, better outcomes
  - Toxicities: Fatigue, hypertension, seizures (enzalutamide)

**CYP17 inhibitors**:
- **Abiraterone**: Blocks androgen synthesis
  - Combined with prednisone (compensatory mineralocorticoid excess)
  - Toxicities: Hypertension, hypokalemia, hepatotoxicity, fluid retention

## Hematopoietic Stem Cell Transplantation

### Autologous Transplant

**Indications**:
- Multiple myeloma
- Relapsed lymphomas
- Germ cell tumors (salvage)

**Process**:
- Stem cell mobilization and collection (G-CSF ± chemotherapy)
- High-dose chemotherapy (myeloablative)
- Stem cell reinfusion
- Recovery (2-3 weeks)

**Toxicities**:
- Severe mucositis
- Prolonged cytopenias, infection
- Organ toxicity (liver, lung, heart)

### Allogeneic Transplant

**Indications**:
- High-risk leukemias, myelodysplastic syndrome
- Relapsed lymphomas (selected)

**Process**:
- HLA-matched donor (sibling, unrelated, haploidentical)
- Conditioning regimen (myeloablative or reduced-intensity)
- Stem cell infusion
- Immune suppression (prevent graft-versus-host disease)

**Graft-versus-host disease (GVHD)**:
- Donor T cells attack recipient tissues
- Acute (<100 days): Skin, liver, GI tract
- Chronic (>100 days): Skin (scleroderma-like), mouth, liver, eyes, lungs
- Treatment: Corticosteroids, calcineurin inhibitors, other immunosuppressants

**Graft-versus-tumor effect**:
- Beneficial immune-mediated anti-cancer activity

**Toxicities**:
- GVHD (major cause of morbidity/mortality)
- Infections (bacterial, viral, fungal)
- Organ toxicity
- Secondary malignancies

## Supportive Care

### Growth Factors

**G-CSF** (filgrastim, pegfilgrastim):
- Stimulate neutrophil production
- Reduce febrile neutropenia risk
- Primary prophylaxis if risk >20%

**Erythropoiesis-stimulating agents (ESAs)**:
- Limited use (thrombotic risk, tumor growth concern)

### Antiemetics

- 5-HT3 antagonists, NK-1 antagonists, dexamethasone
- Olanzapine (highly effective)

### Bone-Targeted Therapy

**Indications**:
- Bone metastases (breast, prostate, lung, myeloma)
- Prevent skeletal-related events (fractures, cord compression, radiation)
- Osteoporosis from ADT or aromatase inhibitors

**Agents**:
- **Denosumab**: RANKL inhibitor, more potent
- **Zoledronic acid**: Bisphosphonate

**Toxicities**:
- Hypocalcemia (monitor, supplement calcium/vitamin D)
- Osteonecrosis of the jaw (dental exam before starting, avoid invasive dental procedures)
- Atypical femur fractures (rare)

### Tumor Lysis Syndrome Prevention

**High-risk tumors**: Burkitt lymphoma, acute leukemias, high tumor burden lymphomas

**Prophylaxis**:
- Hydration
- Allopurinol (xanthine oxidase inhibitor) or
- Rasburicase (uric acid oxidase, more potent)
- Monitor electrolytes, uric acid, creatinine

## Key Points

- Surgery remains the primary curative modality for most solid tumors; margin status (R0 vs R1/R2) is critical for outcomes
- Radiation therapy exploits the "four Rs" (repair, reassortment, repopulation, reoxygenation) through fractionation to maximize tumor kill while sparing normal tissue
- IMRT and SBRT are advanced radiation techniques allowing highly conformal dose delivery with organ sparing for many cancer sites
- Chemotherapy toxicities are predictable: bone marrow suppression (most agents), cardiotoxicity (anthracyclines), peripheral neuropathy (platinum/taxanes), and mucositis/diarrhea (antimetabolites)
- Targeted therapies require identification of molecular targets and are more selective than chemotherapy but can develop resistance through secondary mutations or bypass pathways
- Immune checkpoint inhibitors (anti-PD-1/PD-L1, anti-CTLA-4) have revolutionized treatment of multiple cancers; immune-related adverse events (irAEs) can affect any organ and are managed with corticosteroids
- CAR T-cell therapy can be curative in relapsed lymphomas/leukemias but carries risk of cytokine release syndrome and neurotoxicity requiring specialized management
- Hormonal therapy is cornerstone for ER+ breast cancer (tamoxifen, aromatase inhibitors) and prostate cancer (ADT, AR antagonists, abiraterone)
- Febrile neutropenia (ANC <500, fever ≥38.3°C) is a medical emergency requiring immediate broad-spectrum antibiotics; G-CSF prophylaxis reduces risk in high-risk regimens
- Bone-targeted therapy (denosumab, zoledronic acid) prevents skeletal-related events in bone metastases but requires monitoring for hypocalcemia and osteonecrosis of the jaw

## References

1. DeVita VT, Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 11th ed. Philadelphia, PA: Wolters Kluwer; 2019.

2. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Cancer-Related Fatigue. Version 2.2023.

3. Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 2012;9(3):193-199.

4. Chabner BA, Longo DL. Cancer Chemotherapy and Biotherapy: Principles and Practice. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011.

5. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38(24):2782-2797.

6. Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015;33(28):3199-3212.

7. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158-168.

8. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439-448.

9. Santini D, Pantano F, Vincenzi B, Tonini G. Denosumab in the management of bone disease in cancer patients. Curr Opin Oncol. 2015;27(4):297-303.

10. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844-1854.
